Business
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of
About this update from Biofrontera Inc.
[{"type":"text","content":"WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference CallDate:Friday, April 8, 2022Time:11:00 a.m. Eastern timeConference call:1-877-877-1275 (U.S.)1-412-858-5202 (international)Webcast:Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit https://www.biofrontera-us.com. Contacts Biofrontera Inc.Anke zur Mühlen+1 781 486 [email protected] LHA Investor RelationsTirth T. Patel+1 212 201 [email protected] \nSource: Biofrontera Inc.","length":5060,"tagName":"div"}]